Combining targeted therapeutics in the era of precision medicine

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

(2013) S. A. Flanigan et al.   CLINICAL CANCER RESEARCH

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

(2013) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Finding Trial Designs for Combination Therapies in Oncology

(2013) Sumithra J. Mandrekar   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer

(2013) Miriam Molina-Arcas et al.   Cancer Discovery

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

Cixutumumab

(2009) Kevin P McKian et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS